Th e GINECO trial explored the combination of trastuzumab with paclitaxel and carboplatin in patients with resistant AOC (< 6 months) and HER2 gene amplification. Patients and Methods: A total of ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...

Regardless of stage of disease, cytotoxic chemotherapy remains an important ... of cytotoxic agents to targeted agents, such as with trastuzumab-MCC-DM1. Elucidating the relative importance ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...